Skip to main content
AkademIndex

Products

For developers

AkademBaseOpen API for the ecosystem
← Back to work

Works cited by this work

130 works

Work: Incorporation of immunotherapies and nanomedicine to better normalize angiogenesis-based cancer treatment

  1. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges

    Dai Fukumura, Jonas Kloepper, Zohreh Amoozgar +2

    Review article20183 citations
    ABI

  2. F3-Targeted Cisplatin-Hydrogel Nanoparticles as an Effective Therapeutic That Targets Both Murine and Human Ovarian Tumor Endothelial Cells <i>In vivo</i>

    Ira Winer, Shouyan Wang, Youg-Eun Koo Lee +6

    Article20102 citations
    ABI

  3. Attempts to strengthen and simplify the tumor vascular normalization strategy using tumor vessel normalization promoting nanomedicines

    Shi Du, Hui Xiong, Cheng Xu +2

    Article20192 citations
    ABI

  4. Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models

    Qiaohong Wang, Jingze Gao, Wen Di +1

    Article20202 citations
    ABI

  5. Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes

    Zowi R. Huinen, Elisabeth J. M. Huijbers, Judy R. van Beijnum +2

    Review article20212 citations
    ABI

  6. Angiopoietin inhibitors: A review on targeting tumor angiogenesis

    Parmar Digna, Madhavi Apte

    Review article20212 citations
    ABI

  7. Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation

    Elizabeth Allen, Arnaud Jabouille, Lee B. Rivera +8

    Article20172 citations
    ABI

  8. MMP-9 Supplied by Bone Marrow–Derived Cells Contributes to Skin Carcinogenesis

    Lisa M. Coussens, Christopher L. Tinkle, Douglas Hanahan +1

    Article20002 citations
    ABI

  9. Lenalidomide Synergistically Enhances the Effect of Dendritic Cell Vaccination in a Model of Murine Multiple Myeloma

    Thanh-Nhan Nguyen-Pham, Sung‐Hoon Jung, Manh-Cuong Vo +7

    Article20152 citations
    ABI

  10. Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations

    Р. В. Холоденко, Daniel Kalinovsky, Igor I. Doronin +2

    Review article20192 citations
    ABI

  11. Nanomedicine of synergistic drug combinations for cancer therapy – Strategies and perspectives

    Ruixue Zhang, Ho Lun Wong, Hui Xue +2

    Review article20162 citations
    ABI

  12. Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers

    Rakesh K. Jain

    Review article20132 citations
    ABI

  13. Regulation of tumor angiogenesis and mesenchymal–endothelial transition by p38α through TGF-β and JNK signaling

    Raquel Batlle, Eva Andrés, Lorena González +5

    Article20192 citations
    ABI

  14. Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

    James A. Bonner, Paul M. Harari, J. Giralt +14

    Article20062 citations
    ABI

  15. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

    Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo +17

    Article20182 citations
    ABI

  16. A randomized phase II study with ilixadencel, a cell-based immune primer, plus sunitinib versus sunitinib alone in synchronous metastatic renal cell carcinoma.

    Magnus Lindskog, Anna Laurell, Anders Kjellman +17

    Article20202 citations
    ABI

  17. Untitled

    Other1 citations
    ABI

  18. Untitled

    Other1 citations
    ABI

  19. Untitled

    Other1 citations
    ABI

  20. Untitled

    Other1 citations
    ABI

  21. Untitled

    Other1 citations
    ABI

  22. Untitled

    Other1 citations
    ABI

  23. Untitled

    Other1 citations
    ABI

  24. Untitled

    Other1 citations
    ABI

  25. Untitled

    Other1 citations
    ABI